Xvivo Perfusion AB (publ)
SSE:XVIVO.ST
282 (SEK) • At close February 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) SEK.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 597.542 | 415.292 | 258.386 | 179.861 | 220.838 | 187.868 | 148.342 | 138.177 | 120.245 | 84.702 | 68.922 | 14.724 |
| Cost of Revenue
| 180.629 | 118.336 | 70.107 | 46.886 | 58.024 | 51.915 | 34.946 | 35.942 | 35.285 | 20.656 | 14.785 | 3.312 |
| Gross Profit
| 416.913 | 296.956 | 188.279 | 132.975 | 162.814 | 135.953 | 113.396 | 102.235 | 84.96 | 64.046 | 54.137 | 11.412 |
| Gross Profit Ratio
| 0.698 | 0.715 | 0.729 | 0.739 | 0.737 | 0.724 | 0.764 | 0.74 | 0.707 | 0.756 | 0.785 | 0.775 |
| Reseach & Development Expenses
| 129.252 | 69.343 | 54.039 | 56.178 | 62.651 | 47.931 | 39.469 | 36.67 | 31.086 | 23.921 | 15.194 | 2.314 |
| General & Administrative Expenses
| 76.944 | 70.979 | 55.687 | 30.342 | 24.739 | 22.519 | 20.045 | 24.489 | 13.154 | 11.102 | 12.019 | 5.656 |
| Selling & Marketing Expenses
| 232.261 | 152.398 | 97.688 | 59.899 | 60.786 | 47.948 | 43.702 | 35.708 | 32.052 | 22.669 | 17.051 | 3.253 |
| SG&A
| 249.155 | 223.377 | 153.375 | 90.241 | 85.525 | 70.467 | 63.747 | 60.197 | 45.206 | 33.771 | 29.07 | 8.909 |
| Other Expenses
| -5.432 | -0.219 | -0.393 | 20.869 | 10.666 | 4.075 | 2.881 | 2.037 | 0.537 | -0.726 | -0.395 | 0 |
| Operating Expenses
| 378.407 | 292.501 | 207.021 | 167.288 | 158.842 | 122.473 | 106.097 | 98.904 | 76.829 | 56.966 | 43.869 | 11.223 |
| Operating Income
| 38.506 | 23.181 | 6.982 | -34.313 | 5.633 | 14 | 7.106 | 2.734 | 7.212 | 6.688 | 10.774 | 0.212 |
| Operating Income Ratio
| 0.064 | 0.056 | 0.027 | -0.191 | 0.026 | 0.075 | 0.048 | 0.02 | 0.06 | 0.079 | 0.156 | 0.014 |
| Total Other Income Expenses Net
| 56.015 | -0.867 | -0.317 | -22.95 | -0.343 | 4.018 | 0.153 | -0.338 | -0.733 | -0.364 | 0.45 | -0.073 |
| Income Before Tax
| 94.521 | 22.314 | 6.665 | -57.263 | 5.29 | 17.498 | 7.452 | 2.993 | 7.398 | 6.716 | 10.718 | 0.139 |
| Income Before Tax Ratio
| 0.158 | 0.054 | 0.026 | -0.318 | 0.024 | 0.093 | 0.05 | 0.022 | 0.062 | 0.079 | 0.156 | 0.009 |
| Income Tax Expense
| 2.701 | 3.887 | -1.487 | -13.528 | 0.351 | 4.813 | 1.192 | 1.492 | 2.267 | 2.978 | 2.664 | 0.908 |
| Net Income
| 91.82 | 18.427 | 8.152 | -43.735 | 4.939 | 12.685 | 6.26 | 1.501 | 5.131 | 3.738 | 8.054 | -0.769 |
| Net Income Ratio
| 0.154 | 0.044 | 0.032 | -0.243 | 0.022 | 0.068 | 0.042 | 0.011 | 0.043 | 0.044 | 0.117 | -0.052 |
| EPS
| 3.07 | 0.62 | 0.28 | -1.61 | 0.19 | 0.48 | 0.25 | 0.07 | 0.24 | 0.25 | 0.41 | -0.039 |
| EPS Diluted
| 3.07 | 0.62 | 0.28 | -1.61 | 0.18 | 0.48 | 0.24 | 0.07 | 0.24 | 0.25 | 0.41 | -0.039 |
| EBITDA
| 69.369 | 65.348 | 39.239 | -16.991 | 30.493 | 34.549 | 22.504 | 16.312 | 19.136 | 11.631 | 12.254 | 0.212 |
| EBITDA Ratio
| 0.116 | 0.157 | 0.152 | -0.094 | 0.138 | 0.184 | 0.152 | 0.118 | 0.159 | 0.137 | 0.178 | 0.014 |